Daito Pharmaceutical Co.,Ltd. (TYO:4577)
Japan · Delayed Price · Currency is JPY 1,329.00
+35.00 (2.70%)
Jul 14, 2026, 3:30 PM JST
Daito Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Net Income | 4,065 | 2,958 | 4,218 | 5,076 | 6,720 |
Depreciation & Amortization | 4,387 | 4,332 | 3,659 | 3,870 | 3,313 |
Loss (Gain) From Sale of Assets | 315 | 384 | 165 | 17 | 56 |
Loss (Gain) From Sale of Investments | -331 | -409 | -326 | 87 | -47 |
Loss (Gain) on Equity Investments | 85 | -75 | - | - | - |
Other Operating Activities | -647 | -571 | -1,111 | -2,405 | -1,820 |
Change in Accounts Receivable | 1,334 | -4,891 | 2,221 | -1,502 | -3,299 |
Change in Inventory | 2,021 | 2,419 | -2,640 | -1,413 | -1,041 |
Change in Accounts Payable | -1,934 | -360 | 802 | 538 | 22 |
Change in Other Net Operating Assets | 82 | 2,110 | -1,806 | -113 | 466 |
Operating Cash Flow | 9,377 | 5,897 | 5,182 | 4,155 | 4,370 |
Operating Cash Flow Growth | 59.01% | 13.80% | 24.72% | -4.92% | -15.67% |
Capital Expenditures | -3,818 | -6,789 | -6,220 | -5,505 | -4,627 |
Sale of Property, Plant & Equipment | -31 | -65 | - | - | - |
Cash Acquisitions | - | -707 | - | - | - |
Sale (Purchase) of Intangibles | -1,368 | -241 | -56 | -51 | -106 |
Investment in Securities | 454 | 438 | 335 | - | 256 |
Other Investing Activities | 375 | -1 | 11 | -10 | 77 |
Investing Cash Flow | -4,388 | -7,365 | -5,930 | -5,566 | -4,400 |
Long-Term Debt Issued | - | 6,000 | 4,000 | 3,000 | 1,500 |
Total Debt Issued | - | 6,000 | 4,000 | 3,000 | 1,500 |
Long-Term Debt Repaid | -3,099 | -3,099 | -2,029 | -1,638 | -1,444 |
Total Debt Repaid | -3,099 | -3,099 | -2,029 | -1,638 | -1,444 |
Net Debt Issued (Repaid) | -3,099 | 2,901 | 1,971 | 1,362 | 56 |
Issuance of Common Stock | - | - | - | 302 | 1,527 |
Repurchase of Common Stock | -1,631 | -623 | -1,176 | -110 | - |
Common Dividends Paid | -1,119 | -998 | -907 | -931 | -660 |
Other Financing Activities | -440 | -278 | -71 | -7 | 66 |
Financing Cash Flow | -6,289 | 1,002 | -183 | 616 | 989 |
Foreign Exchange Rate Adjustments | 47 | -54 | 51 | 20 | 48 |
Miscellaneous Cash Flow Adjustments | - | 1 | 1 | 1 | 1 |
Net Cash Flow | -1,253 | -519 | -879 | -774 | 1,008 |
Free Cash Flow | 5,559 | -892 | -1,038 | -1,350 | -257 |
Free Cash Flow Margin | 10.97% | -1.76% | -2.21% | -2.99% | -0.59% |
Free Cash Flow Per Share | 188.99 | -29.32 | -33.08 | -42.65 | -8.39 |
Cash Interest Paid | 129 | 126 | 40 | 13 | 9 |
Cash Income Tax Paid | 640 | 842 | 1,265 | 2,411 | 1,924 |
Levered Free Cash Flow | 2,304 | -4,444 | 330.13 | -918 | -406.63 |
Unlevered Free Cash Flow | 2,385 | -4,367 | 355.75 | -910.5 | -401 |
Change in Working Capital | 1,503 | -722 | -1,423 | -2,490 | -3,852 |